Seamus Fernandez
Stock Analyst at Guggenheim
(2.87)
# 529
Out of 5,368 analysts
113
Total ratings
53.57%
Success rate
38.84%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CDTX Cidara Therapeutics | Maintains: Strong Buy | 35 50 | 22.91 | 118.25% | 3 | May 16, 2025 | |
LLY Eli Lilly | Maintains: Buy | 973 928 | 819.67 | 13.22% | 13 | Apr 14, 2025 | |
MBX MBX Biosciences | Reiterates: Buy | 44 44 | 10.38 | 323.89% | 2 | Apr 10, 2025 | |
ARQT Arcutis Biotherapeut... | Reiterates: Buy | n/a | n/a | n/a | 3 | Apr 3, 2025 | |
VERV Verve Therapeutics | Reiterates: Buy | n/a | n/a | n/a | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 160 160 | 34.57 | 362.83% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 56 | 29.47 | 90.02% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | n/a | n/a | n/a | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | n/a | n/a | n/a | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 137 130 | 81.72 | 59.08% | 11 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 70 | 62.91 | 11.27% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16 | 5.7 | 180.7% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | n/a | n/a | 1 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | n/a | n/a | n/a | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 50 | 21.7 | 130.41% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 65 | n/a | n/a | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 8 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | n/a | n/a | n/a | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 48 75 | n/a | n/a | 5 | Dec 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 27 | n/a | n/a | 3 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 220 | n/a | n/a | 6 | Nov 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 56 54 | 1.47 | 3573.47% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 60 45 | 21.24 | 111.86% | 2 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 36 38 | 74.39 | -48.92% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 35 38 | 24.52 | 54.98% | 3 | Jan 31, 2018 |